Related Experiment Video
Updated: Sep 9, 2025
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Molecular Pharmacological Interventions for Endometrial Cancer: A Comprehensive Review
Wei Qin1, Yazhou Qi2, Qianwen Li2
1Internal Medicine of Integrated Chinese and Western Medicine, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Abstract:
Endometrial cancer, a common malignancy of the female reproductive system, has a rising incidence and complex clinical management due to its diverse molecular subtypes. This review examines the molecular mechanisms underlying EC, particularly the roles of the Bcl-2 family in apoptosis regulation and estrogen receptor signaling in tumor progression. We explore pharmacological interventions targeting these pathways, including BH3 mimetics and selective estrogen receptor modulators, which show promise but face challenges such as resistance and adverse effects. Additionally, we highlight the potential of natural compounds like curcumin, paclitaxel, and Ganoderma lucidum polysaccharides as adjunctive therapies, demonstrating efficacy in preclinical studies and early-phase clinical trials. This review aims to provide insights into the development of personalized therapeutic strategies for EC and to identify opportunities for optimizing clinical outcomes in future treatments.
Insights
This review explores endometrial cancer (EC) molecular mechanisms, focusing on apoptosis regulation and estrogen receptor signaling. It discusses targeted therapies and natural compounds, aiming to improve EC treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Endometrial cancer (EC) is a prevalent female reproductive malignancy with increasing incidence.
- Diverse molecular subtypes contribute to complex clinical management challenges.
- Understanding molecular mechanisms is crucial for developing effective EC treatments.
Purpose of the Study:
- To review the molecular mechanisms of endometrial cancer (EC).
- To examine the roles of Bcl-2 family proteins and estrogen receptor signaling in EC progression.
- To explore current and potential therapeutic strategies for EC.
Main Methods:
- Literature review of molecular mechanisms in endometrial cancer.
- Analysis of pharmacological interventions targeting apoptosis and estrogen signaling.
- Evaluation of natural compounds as adjunctive EC therapies.
Main Results:
- Bcl-2 family proteins regulate apoptosis, while estrogen receptor signaling drives EC progression.
- Pharmacological agents like BH3 mimetics and SERMs show promise but face resistance and side effects.
- Natural compounds (curcumin, paclitaxel, Ganoderma lucidum polysaccharides) exhibit preclinical efficacy.
Conclusions:
- Personalized therapeutic strategies are essential for optimizing EC clinical outcomes.
- Targeting molecular pathways offers potential for novel EC treatments.
- Further research into adjunctive therapies may improve patient prognosis.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules